Cas:56586-13-1 2-methyl-1-cyclohexanecarboxylic acid manufacturer & supplier

We serve Chemical Name:2-methyl-1-cyclohexanecarboxylic acid CAS:56586-13-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-methyl-1-cyclohexanecarboxylic acid

Chemical Name:2-methyl-1-cyclohexanecarboxylic acid
CAS.NO:56586-13-1
Synonyms:6-Methyl-1-cyclohexanecarboxylic acid;2-Methyl-cyclohexancarbonsaeure;MFCD00074907;2-methyl-cyclohexanecarboxylic acid;2-Methylcyclohexane-1-carboxylic acid;2-Methyl-1-cyclohexanecarboxylic acid,mixture of cis and trans;cis/trans 2-methyl-cyclohexane carboxylic acid;EINECS 260-272-3;Cyclohexanecarboxylic acid,2-methyl;2-Methyl-2-cyclohexanoic acid
Molecular Formula:C8H14O2
Molecular Weight:142.19600
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:242.2ºC at 760mmHg
Density:1.025g/cm3
Index of Refraction:n20/D 1.4633(lit.)
PSA:37.30000
Exact Mass:142.09900
LogP:1.89730

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NA 1993 / PGIII
Packing Group:


Contact us for information like 6-Methyl-1-cyclohexanecarboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Methyl-2-cyclohexanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Methyl-1-cyclohexanecarboxylic acid Use and application,2-methyl-cyclohexanecarboxylic acid technical grade,usp/ep/jp grade.


Related News: Importance of evaluating biocatalytic processes during development Reductase, nitrate (acceptor) (uncultured soil bacterium clone D115gene narG fragment) manufacturers The European Commission (EC) has approved MSD and Bayer’s Verquvo for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction. N-benzyl-9-(oxan-2-yl)-7,8-dihydropurin-6-amine suppliers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. N-(3-(dimethylamino)propyl)-2-(2-(2-(2-(6-(tritylamino)hexanamido)thiazole-4-carboxamido)thiazole-4-carboxamido)thiazole-4-carboxamido)thiazole-4-carboxamide vendor & factory.